Next Article in Journal
A Novel System for Spinal Muscular Atrophy Screening in Newborns: Japanese Pilot Study
Next Article in Special Issue
Neonatal Screening on Tandem Mass Spectrometry as a Powerful Tool for the Reassessment of the Prevalence of Underestimated Diseases in Newborns and Their Family Members: A Focus on Short Chain Acyl-CoA Dehydrogenase Deficiency
Previous Article in Journal
Development of a Multiplex Real-Time PCR Assay for the Newborn Screening of SCID, SMA, and XLA
Previous Article in Special Issue
Screening Pathways through China, the Asia Pacific Region, the World
Open AccessArticle

Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service

1
Sheffield Diagnostic Genetics Service (SDGS), Sheffield Children’s NHS Foundation Trust, Western Bank, Sheffield S10 2TH, UK
2
Division of Pharmacy, Diagnostics and Genetics, Sheffield Children’s NHS Foundation Trust, Western Bank, Sheffield S10 2TH, UK
3
Department of Infection, Immunity & Cardiovascular Disease, Faculty of Medicine, Dentistry & Health, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Present address: Genetics Centre, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK.
§
Present address: Pathology Department, Sidra Medicine, Main Hospital, H2M-24091, PO Box 26999, Doha, Qatar.
Present address: Sheffield Bioinformatics Core, Sheffield Biomedical Research Centre, The University of Sheffield, Western Bank, Sheffield S10 2TN, UK.
Int. J. Neonatal Screen. 2019, 5(4), 40; https://doi.org/10.3390/ijns5040040
Received: 1 August 2019 / Revised: 14 October 2019 / Accepted: 24 October 2019 / Published: 5 November 2019
Next generation DNA sequencing (NGS) has the potential to improve the diagnostic and prognostic utility of newborn screening programmes. This study assesses the feasibility of automating NGS on dried blood spot (DBS) DNA in a United Kingdom National Health Service (UK NHS) laboratory. An NGS panel targeting the entire coding sequence of five genes relevant to disorders currently screened for in newborns in the UK was validated on DBS DNA. An automated process for DNA extraction, NGS and bioinformatics analysis was developed. The process was tested on DBS to determine feasibility, turnaround time and cost. The analytical sensitivity of the assay was 100% and analytical specificity was 99.96%, with a mean 99.5% concordance of variant calls between DBS and venous blood samples in regions with ≥30× coverage (96.8% across all regions; all variant calls were single nucleotide variants (SNVs), with indel performance not assessed). The pipeline enabled processing of up to 1000 samples a week with a turnaround time of four days from receipt of sample to reporting. This study concluded that it is feasible to automate targeted NGS on routine DBS samples in a UK NHS laboratory setting, but it may not currently be cost effective as a first line test. View Full-Text
Keywords: newborn screening; next generation sequencing; automation newborn screening; next generation sequencing; automation
Show Figures

Figure 1

MDPI and ACS Style

van Campen, J.C.; Sollars, E.S.A.; Thomas, R.C.; Bartlett, C.M.; Milano, A.; Parker, M.D.; Dawe, J.; Winship, P.R.; Peck, G.; Grafham, D.; Kirk, R.J.; Bonham, J.R.; Goodeve, A.C.; Dalton, A. Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service. Int. J. Neonatal Screen. 2019, 5, 40.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop